DI MARIO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 4.106
EU - Europa 491
AS - Asia 341
OC - Oceania 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.943
Nazione #
US - Stati Uniti d'America 4.098
CN - Cina 260
SE - Svezia 135
FI - Finlandia 119
DE - Germania 84
GB - Regno Unito 53
UA - Ucraina 46
SG - Singapore 39
VN - Vietnam 31
IT - Italia 15
IE - Irlanda 8
IN - India 8
RO - Romania 6
CA - Canada 5
FR - Francia 5
RU - Federazione Russa 5
NL - Olanda 3
RS - Serbia 3
AU - Australia 2
PA - Panama 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BT - Bhutan 1
BZ - Belize 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EU - Europa 1
HR - Croazia 1
IS - Islanda 1
LU - Lussemburgo 1
PL - Polonia 1
PY - Paraguay 1
TR - Turchia 1
Totale 4.943
Città #
Fairfield 584
Chandler 429
Woodbridge 414
Houston 413
Ashburn 305
Wilmington 250
Ann Arbor 244
Jacksonville 219
Cambridge 199
Seattle 191
Princeton 137
San Diego 71
Beijing 66
Medford 63
Nanjing 56
Boardman 47
Helsinki 32
Dong Ket 30
Guangzhou 29
Roxbury 28
Singapore 25
Des Moines 22
Nanchang 20
Norwalk 20
Changsha 19
Hebei 15
Shenyang 14
London 12
Washington 12
Tianjin 11
Falls Church 10
Jiaxing 9
New York 9
Dublin 7
Edinburgh 6
San Jose 6
Auburn Hills 5
Redwood City 5
Borås 4
Chicago 4
Jinan 4
Kharkiv 4
Los Angeles 4
Ogden 4
Tappahannock 4
Belgrade 3
Dallas 3
Horia 3
Indiana 3
Ningbo 3
Timisoara 3
Brisbane 2
Florence 2
Las Vegas 2
Mestre 2
Milan 2
Ottawa 2
Padova 2
Panama City 2
Pune 2
Rockville 2
Shanghai 2
Adana 1
Amsterdam 1
Asunción 1
Augusta 1
Belize City 1
Champlain 1
Copenhagen 1
Dongguan 1
Easton 1
Frankfurt Am Main 1
Frankfurt am Main 1
Fulham 1
Fuzhou 1
Haikou 1
Hangzhou 1
Hanoi 1
Hazleton 1
Hendon 1
Hounslow 1
Keflavik 1
Kilburn 1
Kunming 1
Lehrte 1
Luxembourg 1
Montreal 1
Nürnberg 1
Painesville 1
Philadelphia 1
Phoenix 1
Prague 1
Redmond 1
Saint Petersburg 1
San Francisco 1
Shannon 1
Sofia 1
Stockholm 1
Thimphu 1
Toronto 1
Totale 4.140
Nome #
Natural course of functional dyspepsia after Helicobacter pylori eradication: A seven-year survey 146
Nuclear DNA content and pathology in radically treated pancreatic carcinoma. The prognostic significance of DNA ploidy, histology and nuclear grade. 145
Actual role of pepsinogen group I in the study of upper gastrointestinal diseases 117
H-pylori eradication and gastric precancerous lesions 113
The appearance of gord in patients with duodenal ulcer after eradication of Helicobacter pylori (Hp) infection: A 4 year prospective study. 106
Laboratory medicine in ulcer disease. 103
Serum pepsinogen C: a useful marker of Helicobacter pylori eradication? 101
Chronic nicotine intake causes vascular dysregulation in the rat gastric mucosa. 99
Serum pepsinogens A and C in monitoring Helicobacter pylori (Hp) status after the cure: A prospective 4 year study. 97
Helicobacter pylori non-cytotoxic genotype enhances mucosal gastrin and mast cell tryptase 96
Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: One or two weeks? 95
Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology 93
Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years' endoscopical survey 89
Pepsin concentration in gastroduodenal biopsy homogenates in chronic ulcer disease. 88
Pepsinogen group I radioimmunoassay and total serum pepsinogen colorimetric determination: a comparative study in normal subjects and in peptic ulcer patients 86
Early epigastric pain after PPI administration: Exacerbation of Helicobacter pylori corpus gastritis? 83
Recovery of gastric function after helicobacter pylori eradication in subjects with body atrophic gastritis: Prospective 4-year study 76
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 75
The long term outcome of gastric non-invasive neoplasia. 74
Polymorphonuclear oxidative burst after Helicobacter pylori water extract stimulation is not influenced by the cytotoxic genotype but indicates infection and gastritis grade. 74
Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. 73
Measurement of tryptase in endoscopic gastroduodenal biopsies: distribution and relationship with ulcer disease. 72
Retreatment after failure of Helicobacter pylori eradication: Quadruple vs ranitidine bismuth citrate 2 weeks therapy. 69
Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. 67
Gastric epithelial dysplasia and sulphomucin-type intestinal metaplasia. 67
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. 67
Identification of the phenotype of the gastric mucosa in patient's with Barrett's esophagus with and without H-pylori infection 66
Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection 66
Relationship between psychosocial factors and serum level of pepsinogen group I and gastrinemia in the normal subject. 64
Carcinogenetic potential of the WSR cagA region. 64
EARLY AND ADVANCED GASTRIC-CANCER IN THE FOLLOW-UP OF MODERATE AND SEVERE GASTRIC DYSPLASIA PATIENTS - A PROSPECTIVE-STUDY 64
Interferon gamma (IFNg) and interleukin-10 (IL-10) Haplotypes differently influence Helicobacter pylori infection outcome 63
Helicobacter pylori activates gastric mucosal mast cells. 61
Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions 61
Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. 61
Effect of storage time on peptic activity in gastric biopsies. 60
Serum Pepsinogen Assays and Gastric Acid Secretion 59
PPIS plus H-2-antagonists for non-responders GERD patients: A rescue therapy? (A three months pilot study). 59
Discriminant analysis in the clinical and biochemical diagnosis of primary liver cancer. 58
The outcome of low and high grade of chronic atrofic gastritis (CAG) after Helicobacter pylori infection eradication: A 3 years follow-up 57
Radioimmunoassay for pepsinogen C 55
Utilità  clinica della curva gastrinemica dopo pasto proteico nella malattia ulcerosa duodenale. 52
Identification of new IL12A and IL12B genes polymorphisms as host genetic factors interplaying with H. pylori 52
Carcinogenetic potential of the WSR cagA region of Helicobacter pylori. 52
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages 50
Limits of CEA and ferritin in the diagnosis of pancreatic cancer. 50
Carcinogenetic potential of the WSR CagA region of Helicobacter pylori 48
[Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis]. 48
Diagnosis of Helicobacter pylori infection: comparison of techniques. 47
[Morpho-functional characteristics of reflux gastritis in patients after cholecystectomy and without cholecystectomy]. 47
The "very bed" H pylori: Experience on 69 consecutive patients after the failure of the second eradication treatment. 45
Measurement of pepsinogen group I in endoscopic gastroduodenal biopsies. 45
Synergistic effect of H. pylori infection and interleukin 12 polymorphisms for the development of gastric cancer 44
[Ca 19-9 in the diagnosis of pancreatic carcinoma]. 44
Il Ca 19-9 nella diagnosi di carcinoma pancreatico 44
Benign and malignant gastric ulcers: is their localization relevant in their differential diagnosis? 43
[Gastrin tissue levels in patients with peptic ulcer: a different methodological approach]. 42
Gastric juice polymerase chain reaction: an alternative to histology in the diagnosis of Helicobacter pylori infection. 42
The dark side of the gastric biopsy 40
[Does Helicobacter pylori have a direct proteolytic effect in ulcerative disease?]. 40
Do ranitidine and nizatidine influence pepsin secretion? 39
Comparison of different dosages of PPI in one-week Helicobacter pylori eradication therapy 39
[Raised levels of IgE and allergic diseases in patients subjected to esophagogastroduodenoscopy]. 38
The role of the laboratory in the diagnosis and monitoring of Helicobacter pylori infection. 37
GASTRIC INVOLVEMENT IN PRIMARY SJOGRENS-SYNDROME 37
[Basal and postprandial blood gastrin in peptic ulcer. The physiopathological aspects in relation to different sites of the lesion]. 36
[Alcohol-dependent mast cell activation in ulcer]. 36
[Gastric ulcer, duodenal ulcer and major and minor blood groups. Epidemiological aspects, functional correlations, clinical implications]. 36
Virulence H. pylori genes cagA and oipA interplay with IL1b and IL-1RN host genes in favoring preneoplastic and neoplastic gastric lesions 35
[The effects of nizatidine and misoprostol on peptic activity and gastric mucus]. 35
Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD 32
Virulence H. pylori genes cagA and oipA interplay with IL1b and IL1-RN host genes in favoring preneoplastic and neoplastic gastric lesions 31
[Pepsinogen]. 30
[Cigarette smoking and group I pepsinogen levels. Study in a normal population]. 30
Effects of H2 blockers and omeprazole on peptic secretion: a prospective, randomized study in duodenal ulcer subjects. 30
Early fall of anti Helicobacter pylori IgG in eradicated patients with non-ulcer dyspepsia. 29
High IgE serum levels and "peptic" ulcers: clinical and functional approach. 29
Tumor necrosis factor alpha (TNFa), Interferon Gamma (IFNg), IL10 host gene polymorphisms and H. pylori infection 28
Serological tests to monitor treatment of Helicobacter pylori 26
Atlante a colori delle malattie dell'apparato digerente. Malattie dello stomaco. 25
Virulence H. pylori genes cagA and oipA interplay with IL1b and IL-1RN host genes in favoring preneoplastic and neoplastic gastric lesions 24
Gastric bicarbonate secretion in high-relapsing, smoking duodenal ulcer patients. 22
Smoking habit on gastric bicarbonate secretion in patients with duodenal ulcer. 21
The natural history of duodenal ulcer disease. 18
Does alcohol activate mast cells in peptic ulcer? 15
Esaprazole effect on acid, peptic and alkaline secretion in duodenal ulcer patients. 14
Pathophysiology of the gastric microcirculation. 10
Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED) 3
Totale 4.949
Categoria #
all - tutte 17.999
article - articoli 16.613
book - libri 98
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.710


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019140 0 0 0 0 0 0 0 0 0 0 0 140
2019/2020907 173 21 11 56 96 67 82 103 94 109 58 37
2020/2021564 29 36 16 101 20 54 7 35 86 38 76 66
2021/2022955 12 154 76 85 68 48 36 109 30 13 96 228
2022/2023879 175 84 3 103 173 111 1 74 93 4 48 10
2023/2024346 19 59 47 26 42 66 20 11 9 7 37 3
Totale 4.949